Abstract 3275: Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Siwen Hu-Lieskovan, James Moon, John Hyngstrom, Katie M. Campbell, Gino K. In, Theodore F. Logan, Kari L. Kendra, Ding M. Wang, Douglas B. Johnson, Gary C. Doolittle, Alan Tan, Ann W. Silk, Kenneth F. Grossmann, Christopher W. Ryan, Sapna P. Patel, Shay Bellasea, Michael C. Wu, John M. Kirkwood, Helen X. Chen, Antoni Ribas
Institutions: Huntsman Cancer Institute, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, The Ohio State University, Henry Ford Health, Henry Ford Hospital, Vanderbilt University, The University of Kansas Cancer Center, Cancer Treatment Centers of America, Dana-Farber Cancer Institute, Oregon Health & Science University, The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4362593105